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PSA PERSPECTIVES:
ASSESSING PATIENT KNOWLEDGE ABOUT
PSA TESTING & FACILITATING A
CONVERSATION ABOUT RISKS AND
BENEFITS
Kirsten Martin
Family Medicine Rotation 5, October-November, 2018
New Milford, Connecticut
Dr. Peter Anderson, MD

Problem Identification
•

New recommendations from US Preventive Services Task Force
(USPSTF) advise physicians discuss the risks and benefits of PSA
screening with men age 55-69 to determine who gets screened, after
previously advising against screening altogether

•

Having a conversation about this screening test can take a significant
amount of time to adequately educate patients about this
controversial test

•

There are limited resources available to PCPs to facilitate this
conversation.

•

Recommendations are conflicting and continue to change, further
complicating the decision for patients and providers.

Cost Considerations
•

The cost per year of life saved by prostate cancer
screening with PSA and DRE was
•
•
•

$2339-3005 for men aged 50-59,
$3905-5070 for men aged 60-69, and
$3574-4627 overall for men aged 50-69

•

Prostate cancer screening by Medicare amounted to
$447 million in 2009 US dollars

•

The 3-year cost to Medicare for prostate cancer
detection in men 70 years or older is approximately $1.2
billion.

Community (Patient) Perspective
•

The majority of men interviewed reported that they knew
very little about prostate cancer screening and prostate
cancer.

•

When asked what they would want to know about a
screening test, men reported
•
•

•

“I would want to know if it works. If it works then great, as long
as it is not going to have any side effects.”
“What is involved in getting the test itself, why do I need to get
it, and when?”

When asked how effective a screening test would need to
be for a man to consider having it done, patients reported:
•

“I would just be acting with the assumption that it would be
completely accurate.”

Community (Patient) Perspective
•

When asked about PSA screening specifically, men were less likely to want screening after
hearing that the screening does not decrease the chances of dying from prostate cancer.

•

Men reported that they value the recommendation of their PCP regarding whether or not to
have screening done

•

The outcomes of screening and available treatments were important to patients considering
screening:
•

“Give me some good reasons to get the screening and the treatment [and I will do it]. But … if
you can’t do anything about it, then what’s the point ….”

Intervention
•

Create a handout about the risks and benefits of PSA screening intended to
•
•
•

Decrease office time spent educating patients about PSA screening and allow more time
to discuss other health concerns
Equip patients with an understanding of PSA screening, risks and benefits, and the
potential consequences of a positive test
Empower patients to make screening decisions based on their unique values

Response to Intervention
•

Patients seemed interested in learning more about PSA screening because they
hear “cancer” and immediately want to be tested.

•

Having the handout to give to patients helped facilitate the conversation and give
people a chance to think over the potential consequences of a positive test before
choosing to be screened.

Evaluation of Effectiveness
•

Survey patients about their confidence about their
understanding of the following before and after receiving
the handout and having a discussion with their physician
• What is PSA screening?
• What are the consequences of a positive test?
• What is involved in the treatment of prostate cancer?
• What are the risks and benefits of receiving treatment
for prostate cancer?
• Should I be screened for prostate cancer?

•

**The effectiveness was not evaluated in this project due
to the short duration of the research

Limitations
•

A handout can only do so much to
facilitate a discussion between a patient
and a provider.

•

Providers must remain diligent about
educating their patients about PSA
screening.

•

Patient perspectives were only collected
from one clinic, so there is limited diversity
in cultural backgrounds, relationship with
PCP, and other important factors

Future Interventions
•

Better screening tests for prostate cancer may
be developed with the advances in medical
imaging and genetic testing

•

More specific recommendations should be
developed to identify patients at higher risk for
the more aggressive forms of prostate cancer

•

A risk calculator could be developed to assist in
the decision to screen patients for prostate
cancer

•

Better treatments targeted to the genetic
mutations present in a given patient’s cancer
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